


Nanopore sequencing technology



Modified from Wang, Y., Zhao, Y., Bollas, A. et al. Nanopore sequencing technology, bioinformatics and applications. Nat Biotechnol 39, 1348–1365 (2021)

Example of method application – questions to answer:

 Does expression of non-coding-RNA (ncRNA) encoding genes is different in Glioblastoma vs Low-grade-glioma (GBM

Challenges in the Next Generation (Oxford Nanopore) direct RNA Sequencing (dRNA-seq) Data Processing: Coping With Normalisation of Gene Expression Levels by Principal Component Analysis

> A.Kriščiukaitis^{1,2}, R.Petrolis^{1,2}, R.Dragunaitė², R.Stakaitis², D.Skiriutė² ¹ Dept. Physics, Mathematics and Biophysics, Lithuanian University of Health Sciences ² Neuroscience Institute, Lithuanian University of Health Sciences

Introduction: Next generation sequencing (NGS) is getting **The list of HKG**: [Trends in Genetics 29 (2013), 569–574] widely applicable for the detection of molecular markers in modern medical diagnostics. However, processing and evaluation of RNA-seq data is challenging due to some inescapable physical factors causing certain bias in the analyzed data.


Problem: Technical differences ("batch effects") caused by differences in sample processing (up to RNA extraction, RNAseq library preparation or the number of live pores) may significantly affect the ability to draw generalizable conclusions from such studies.

The Aim: Elaboration of the method for gene expression level analysis avoiding bias caused by inescapable physical factors in RNA-seq data.

Gene Name	Gene description
C1orf43	chromosome 1 open reading frame 43
CHMP2A	charged multivesicular body protein 2A
EMC7	ER membrane protein complex subunit 7
GPI	glucose-6-phosphate isomerase
PSMB2	proteasome subunit, beta type, 2
PSMB4	proteasome subunit, beta type, 4
RAB7A	member RAS oncogene family
REEP5	receptor accessory protein 5
SNRPD3	small nuclear ribonucleoprotein D3
VCP	valosin containing protein
VPS29	vacuolar protein sorting 29 homolog


Solution: The key solution to normalization of gene expression levels estimated across different samples lays in so called *housekeeping genes (HKG)*, which are required for the maintenance of the basal cell functions. Thus, they are expected to be equally expressed in all cells.

- vs LGG) cases?
- If yes, of which genes?



normalized gene expression levels data set: $R_x = E | X \cdot X^T |$

Contribution of first eigenvectors of covariation matrix in representation of total variance in analyzed data



 $PC1_X_i = W_{11}X_{1i} + W_{12}X_{2i} + \dots + W_{1n}X_{ni}$ PC1 PC2 GBM LGG GBM LGG **Relative Units Relative Units**

Results: ncRNAs encoding genes which expression differs between GBM and LGG cases.

PCA aggregates the information from correlated variables into a smaller set of uncorrelated variables (the principal components). If HKG are expected to be equally expressed in all cells, their expression levels should be aggregated into the principal component, representing technical differences ("batch effects"). On the other hand, we can expect that expression levels of genes, which significantly differ between investigated groups (GBM vs LGG) will be aggregated into **Expected results:** Ideally, the PC representing some other PC.

Eigenvectors of covariation matrix R:

$$eig(R) \Longrightarrow [\varphi_1, \varphi_2, \dots, \varphi_n]$$

Ordinary eigenvector φ_i (PCi): $\varphi_i = [w_{i1}, w_{i2}, \dots w_{in}]$


differences between maximal investigated pathology groups and having lowest contribution of any HKG to it, should be considered for search of genes - candidate biomarkers of investigated pathology.


Internal coefficients of each PC represent contribution of each variable to the component. So, the highest coefficients show the most important variables (expression of genes encoding IncRNA) in this component. Therefore, in real situation, we expect that contribution of HKG expression to the sought PC will be substantially lesser than candidate biomarkers of investigated pathology.

Results: PC1, representing 12.35% of total variance shoved the biggest difference in regard to the pathology type. Contribution of HKG expression in it was negligible. At the same time, PC2, representing 7.69% of total variance, showed non-significant difference between pathology type. The contributions of expression of two HKG were among Top3 in the whole list of this component. So, PC1 was used to search for candidate biomarkers.

200

Truncated representation of initial data by particular eigenvector: $PC2_X_i = W_{21}X_{1i} + W_{22}X_{2i} + \dots + W_{2n}X_{ni}$





Conclusions: Application of Principal Component Analysis to RNA-seq data revealed particular ncRNA encoding genes most differently expressed in the samples of Glioblastoma and Low-grade-glioma. The ncRNAs encoded by COPG2IT1 and SNGH14, together with OIP5-AS1, NORAD, NEAT1, and MIR4435-2HG could be the candidates for biomarkers differentiating Glioblastoma and Low-grade-glioma cases.

Aknowledgements: This study was funded from Research Council of Lithuania (LMT) Grants: S-SEN-20-7 and MIP-20-51.



VCP